{
    "nctId": "NCT05562518",
    "briefTitle": "GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.",
    "officialTitle": "GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.",
    "overallStatus": "RECRUITING",
    "conditions": "Vulvovaginal Atrophy, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 160,
    "primaryOutcomeMeasure": "Change in symptoms and quality of life after implementation of treatment in a time frame of 12 weeks using the EQ5D-questionnaire.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* breast cancer patient\n* current endocrine therapy (AI or SERM)\n* postmenopausal status, defined by:\n\n  * 12 months amenorrhoea or\n  * 6 months amenorrhoe and FSH level of \\>40 mIU/mL or\n\n    \\*\\>6 weeks after bilateral oophorectomy or\n  * induced postmenopause (ovarian function suppression using GnRH-analogue)\n* presence of one or more symptoms of vulvovaginal atrophy (dyspareunia, dryness, irritation)\n\nExclusion Criteria:\n\n* a history of vulvar or vaginal surgery\n* current other vulvar or vaginal disease\n* recent use of antibiotics/antifungals/corticosteroids (less than 1 month)\n* current use of vaginal hormonal treatment or vaginal moisturizer: inclusion is possible after a washout period of 4 weeks",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}